Macquarie Group LTD Travere Therapeutics, Inc. Transaction History
Macquarie Group LTD
- $87.4 Billion
- Q1 2024
A detailed history of Macquarie Group LTD transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 4,613,059 shares of TVTX stock, worth $45.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
4,613,059
Previous 4,746,776
2.82%
Holding current value
$45.2 Million
Previous $42.7 Million
16.65%
% of portfolio
0.04%
Previous 0.05%
Shares
14 transactions
Others Institutions Holding TVTX
# of Institutions
185Shares Held
89.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$76.4 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$73.5 Million0.79% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$72.2 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$64.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$61.4 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $629M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...